Cargando…

A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes

OBJECTIVE: Silent myocardial infarction (MI) is a prevalent finding in patients with type 2 diabetes and is associated with significant mortality and morbidity. Late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR) is the most validated technique for detection of silent MI, bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Swoboda, Peter P., McDiarmid, Adam K., Erhayiem, Bara, Haaf, Philip, Kidambi, Ananth, Fent, Graham J., Dobson, Laura E., Musa, Tarique A., Garg, Pankaj, Law, Graham R., Kearney, Mark T., Barth, Julian H., Ajjan, Ramzi, Greenwood, John P., Plein, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377587/
https://www.ncbi.nlm.nih.gov/pubmed/27300573
http://dx.doi.org/10.1210/jc.2016-1318
_version_ 1782519338854514688
author Swoboda, Peter P.
McDiarmid, Adam K.
Erhayiem, Bara
Haaf, Philip
Kidambi, Ananth
Fent, Graham J.
Dobson, Laura E.
Musa, Tarique A.
Garg, Pankaj
Law, Graham R.
Kearney, Mark T.
Barth, Julian H.
Ajjan, Ramzi
Greenwood, John P.
Plein, Sven
author_facet Swoboda, Peter P.
McDiarmid, Adam K.
Erhayiem, Bara
Haaf, Philip
Kidambi, Ananth
Fent, Graham J.
Dobson, Laura E.
Musa, Tarique A.
Garg, Pankaj
Law, Graham R.
Kearney, Mark T.
Barth, Julian H.
Ajjan, Ramzi
Greenwood, John P.
Plein, Sven
author_sort Swoboda, Peter P.
collection PubMed
description OBJECTIVE: Silent myocardial infarction (MI) is a prevalent finding in patients with type 2 diabetes and is associated with significant mortality and morbidity. Late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR) is the most validated technique for detection of silent MI, but is time-consuming, costly, and requires administration of intravenous contrast. We therefore planned to develop a simple and low-cost population screening tool to identify those at highest risk of silent MI validated against the CMR reference standard. METHODS: A total of 100 asymptomatic patients with type 2 diabetes underwent electrocardiogram (ECG), echocardiography, biomarker assessment, and CMR at 3.0T including assessment of left ventricular ejection fraction and LGE. Global longitudinal strain from two- and four-chamber cines was measured using feature tracking. RESULTS: A total of 17/100 patients with no history of cardiovascular disease had silent MI defined by LGE in an infarct pattern on CMR. Only four patients with silent MI had Q waves on ECG. Patients with silent MI were older (65 vs 60, P = .05), had lower E/A ratio (0.75 vs 0.89, P = .004), lower GLS (–15.2% vs –17.7%, P = .004), and higher amino-terminal pro brain natriuretic peptide (106 ng/L vs 52 ng/L, P = .003). A combined risk score derived from these four factors had an area under the receiver operating characteristic curve of 0.823 (0.734–0.892), P < .0001. A score of more than 3/5 had 82% sensitivity and 72% specificity for silent MI. CONCLUSIONS: Using measures that can be derived in an outpatient clinic setting, we have developed a novel screening tool for the detection of silent MI in type 2 diabetes. The screening tool had significantly superior diagnostic accuracy than current ECG criteria for the detection of silent MI in asymptomatic patients.
format Online
Article
Text
id pubmed-5377587
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-53775872017-09-01 A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes Swoboda, Peter P. McDiarmid, Adam K. Erhayiem, Bara Haaf, Philip Kidambi, Ananth Fent, Graham J. Dobson, Laura E. Musa, Tarique A. Garg, Pankaj Law, Graham R. Kearney, Mark T. Barth, Julian H. Ajjan, Ramzi Greenwood, John P. Plein, Sven J Clin Endocrinol Metab Original Article OBJECTIVE: Silent myocardial infarction (MI) is a prevalent finding in patients with type 2 diabetes and is associated with significant mortality and morbidity. Late gadolinium enhancement (LGE) by cardiovascular magnetic resonance (CMR) is the most validated technique for detection of silent MI, but is time-consuming, costly, and requires administration of intravenous contrast. We therefore planned to develop a simple and low-cost population screening tool to identify those at highest risk of silent MI validated against the CMR reference standard. METHODS: A total of 100 asymptomatic patients with type 2 diabetes underwent electrocardiogram (ECG), echocardiography, biomarker assessment, and CMR at 3.0T including assessment of left ventricular ejection fraction and LGE. Global longitudinal strain from two- and four-chamber cines was measured using feature tracking. RESULTS: A total of 17/100 patients with no history of cardiovascular disease had silent MI defined by LGE in an infarct pattern on CMR. Only four patients with silent MI had Q waves on ECG. Patients with silent MI were older (65 vs 60, P = .05), had lower E/A ratio (0.75 vs 0.89, P = .004), lower GLS (–15.2% vs –17.7%, P = .004), and higher amino-terminal pro brain natriuretic peptide (106 ng/L vs 52 ng/L, P = .003). A combined risk score derived from these four factors had an area under the receiver operating characteristic curve of 0.823 (0.734–0.892), P < .0001. A score of more than 3/5 had 82% sensitivity and 72% specificity for silent MI. CONCLUSIONS: Using measures that can be derived in an outpatient clinic setting, we have developed a novel screening tool for the detection of silent MI in type 2 diabetes. The screening tool had significantly superior diagnostic accuracy than current ECG criteria for the detection of silent MI in asymptomatic patients. Endocrine Society 2016-06-14 /pmc/articles/PMC5377587/ /pubmed/27300573 http://dx.doi.org/10.1210/jc.2016-1318 Text en Copyright © 2016 Endocrine Society https://creativecommons.org/licenses/by/4.0/ This article has been published under the terms of the Creative Commons Attribution License (CC BY; https://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Swoboda, Peter P.
McDiarmid, Adam K.
Erhayiem, Bara
Haaf, Philip
Kidambi, Ananth
Fent, Graham J.
Dobson, Laura E.
Musa, Tarique A.
Garg, Pankaj
Law, Graham R.
Kearney, Mark T.
Barth, Julian H.
Ajjan, Ramzi
Greenwood, John P.
Plein, Sven
A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes
title A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes
title_full A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes
title_fullStr A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes
title_full_unstemmed A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes
title_short A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes
title_sort novel and practical screening tool for the detection of silent myocardial infarction in patients with type 2 diabetes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5377587/
https://www.ncbi.nlm.nih.gov/pubmed/27300573
http://dx.doi.org/10.1210/jc.2016-1318
work_keys_str_mv AT swobodapeterp anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT mcdiarmidadamk anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT erhayiembara anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT haafphilip anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT kidambiananth anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT fentgrahamj anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT dobsonlaurae anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT musatariquea anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT gargpankaj anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT lawgrahamr anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT kearneymarkt anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT barthjulianh anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT ajjanramzi anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT greenwoodjohnp anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT pleinsven anovelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT swobodapeterp novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT mcdiarmidadamk novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT erhayiembara novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT haafphilip novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT kidambiananth novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT fentgrahamj novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT dobsonlaurae novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT musatariquea novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT gargpankaj novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT lawgrahamr novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT kearneymarkt novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT barthjulianh novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT ajjanramzi novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT greenwoodjohnp novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes
AT pleinsven novelandpracticalscreeningtoolforthedetectionofsilentmyocardialinfarctioninpatientswithtype2diabetes